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Executive summary 
In 2016, the World Health Assembly endorsed the first global health sector strategy on viral hepatitis. 
The aim of the strategy is to eliminate viral hepatitis as a major public health threat by 2030. In 
Europe, people who inject drugs (PWID) are at high risk of hepatitis C virus (HCV) and hepatitis B 
virus (HBV) transmission and constitute a key group for the elimination strategy. Chronic viral 
hepatitis can result in serious liver diseases such as cirrhosis and cancer and is associated with a 
high burden of disease. As a complement to the existing monitoring platform, the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is working with its expert network on 
drug-related infectious diseases (the DRID network) on a PWID-specific list of epidemiological 
indicators — the elimination barometer — in order to help EU Member States to identify data gaps 
and assess progress towards the elimination of HCV and HBV in this group. 
The elimination barometer includes five building blocks (context and needs, inputs, prevention, testing 
and linkage to care, and impact) and 17 indicators covering the EU, Norway and Turkey until the last 
quarter of 2018. The sources of the data include the EMCDDA data collection tools that collate data 
from the EMCDDA national focal points (Fonte for quantitative data and the Reitox workbooks for 
qualitative information), information shared by the national DRID experts and published reports. The 
2020 targets were taken from the World Health Organization’s regional action plan for viral hepatitis in 
the European region. 
In the 15 national studies conducted between 2015 and 2018, the estimated prevalence of injecting 
drug use at national level ranged from less than 1 per 1 000 to more than 5 per 1 000. Sharing of 
injecting equipment is frequently reported by drug users. In 8 out of the 14 countries with national data 
on HCV antibody prevalence for 2016-17, more than half of people who inject drugs have been 
infected with HCV. Among the four countries collecting data on the prevalence of chronic infections 
among PWID, the prevalence ranged from 23.1 % in Germany (local study) to 55.6 % in Austria. In 
the five countries with national data on HBV prevalence in 2016-17, between 1.4 % and 9.4 % of 
injecting drug users were estimated to be currently infected. By the end of 2018, 18 countries had a 
national hepatitis policy in place. In 2017, 4 and 11 countries were on target, respectively, for sterile 
needle/syringe distribution and opioid substitution treatment coverage. In 2018, hepatitis B 
vaccination was routinely offered to prisoners in 13 countries. While at least some harm reduction 
services offered HCV testing to drug users in 22 EU Member States, in only four did more than 50 % 
of drug treatment entrants report having been tested for HCV in the last 12 months in 2017. In 2018, 
clinical guidelines restricted access to HCV treatment for people who inject drugs in eight EU Member 
States. Data on the prevalence of HCV among young and new injectors suggest that transmission 
remained at high levels in 2017. 
While the available data show that the burden of HCV and HBV among PWID is high, there are still 
information gaps in many countries, including a lack of core data on denominators (the size of the 
PWID population) and routine prevalence estimates for chronic HCV infections among PWID. The 
coverage of measures known to prevent HCV and HBV infections among this group is suboptimal in 
many Member States. There is currently no systematic collection of data on the HCV and HBV 
cascade of care for PWID in Europe. The coverage of testing in the last year among PWID reflects 
missed opportunities to diagnose people in drug treatment services and prisons, while financial and 
clinical restrictions still constitute barriers to direct-acting antiviral treatment. Scaling up of equitable 
and tailored prevention measures, testing and treatment for PWID is needed to have an impact and to 
reach the elimination targets. 
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Introduction 
An estimated 9 million Europeans live with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV), 
including many with an undiagnosed infection. Chronic viral hepatitis can result in serious liver 
diseases such as cirrhosis and cancer. Following the global health strategy on viral hepatitis (WHO, 
2016a), the World Health Organization Regional Office for Europe (WHO Europe) produced an action 
plan for the health sector response to viral hepatitis in the WHO European Region (WHO, 2017a). The 
goal is to achieve a reduction in the incidence of chronic HBV and HCV infections of 30 % by 2020 
and 90 % by 2030, and a reduction in mortality from chronic HBV and HCV infections of 10 % by 2020 
and 65 % by 2030. 
Five key interventions constitute the so-called source code of the elimination strategy. Each key 
intervention comes with a target for the year 2020: HBV vaccine coverage (95 % for three doses in 
infants and 90 % for prevention of mother-to-child transmission), blood donations screened with quality 
assurance (100 %), medical injections with safety-engineered devices (50 %), sterile syringes and 
needles distributed per person who injects drugs per year (200), and diagnosis and treatment of HBV 
and HCV (50 % and 75 %, respectively). In addition to those key interventions, the WHO evaluation 
and monitoring framework (WHO, 2016b) includes indicators on the context (describing the population 
in need and the prevalence of infection), the policy environment (inputs) and the impact (in terms of 
incidence and mortality). Based on this framework, the European Centre for Disease Prevention and 
Control (ECDC) put in place an EU hepatitis B and C monitoring platform. 
People who inject drugs are a key group for the elimination strategy. As a complement to the general 
monitoring platform, the EMCDDA is working with its expert network on drug-related infectious 
diseases (the DRID network) on a list of epidemiological indicators specifically for people who inject 
drugs (PWID) — the elimination barometer — in order to identify data gaps and assess progress 
towards the elimination of HCV and HBV in this group. 
We document here each of the five building blocks of the elimination barometer by looking at the 
European overview for each of the indicators available by the last quarter of 2018. Corresponding 
country-specific data are presented in the annex tables. For each building block, we also provide case 
studies to illustrate the national contexts and experiences that were presented by national experts 
during the DRID network meeting in September 2018. 
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Methods 
Figure 1 provides the list of key indicators of the elimination barometer. Tables 1-5 detail the case 
definitions, methods and data sources used to obtain these indicators. The case studies providing 
national contextual information were presented and reviewed by the national DRID experts. 
 
FIGURE 1  
List of indicators and related targets included in the elimination barometer for viral hepatitis 
among people who inject drugs (PWID) in Europe 
 
* DAA = direct-acting antiviral 
Source: EMCDDA based on (WHO, 2016b). 
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TABLE 1 
Context and need, viral hepatitis elimination barometer for PWID 
Area Indicator Definition Methods Data 
sources 
Related 
2020 target 
1.
 C
on
te
xt
 a
nd
 n
ee
d 
Number of injectors 
among people 
entering drug 
treatment 
People aged between 15 and 64 years entering drug treatment 
services who reported injecting their primary drug 
 
European countries systematically collect data on people entering drug 
treatment through the treatment demand indicator (TDI) 
EMCDDA 
TDI  
Recent data 
available 
(2015 or 
later) 
Number of PWID 
and prevalence of 
injecting drug use 
People aged between 15 and 64 years who have injected any 
psychoactive substance(s) not according to medical 
prescription in the last 12 months (current injector). The 
prevalence of injecting drug use in a given country is the 
number of PWID estimated for a given year divided by the 
population aged 15 to 64 years provided by Eurostat (x 1 000) 
Indirect statistical methods: treatment multipliers (TMs), capture-recapture 
(CRC) methods and single-source truncated Poisson (TP) methods  
EMCDDA 
problem 
drug use 
(PDU) 
indicator 
Recent data 
available 
(2015 or 
later) 
Main drugs injected 
 
Most frequently reported primary substance(s) injected by 
PWID entering treatment 
European countries systematically collect data on people entering drug 
treatment through the TDI, including self-reported primary substance 
 
EMCDDA 
TDI  
Recent data 
available 
(2015 or 
later) 
Prevalence of 
needle/syringe 
sharing 
Proportion of injectors who have injected in the last month who 
reported sharing (receiving or passing on) used 
needles/syringes 
 
 
Surveys conducted among PWID. In some cases, seroprevalence studies 
are combined with the collection of behavioural data 
 
European countries systematically collect data on people entering drug 
treatment through the TDI, including self-reported sharing of injecting 
material 
EMCDDA 
DRID 
indicator 
 
EMCDDA 
TDI  
Recent data 
available 
(2015 or 
later) 
Prevalence of 
hepatitis C 
antibodies among 
PWID 
Proportion of current injectors (drug users who have injected in 
the last 12 months, unless otherwise stated (1)) who tested 
positive for antibodies to HCV 
 
 
Seroprevalence studies (2) designed to obtain information on the 
prevalence of HCV biomarkers among PWID 
 
Routine diagnostic tests, where the positivity rate (the proportion of people 
testing positive among all people tested in a given period) is obtained from 
routine screening and diagnostic tests done by health services 
EMCDDA 
DRID 
indicator 
 
Recent data 
available 
(2015 or 
later) 
Prevalence of 
chronic and/or 
current hepatitis C 
infection among 
PWID 
Proportion of current injectors (drug users who have injected in 
the last 12 months, unless otherwise stated (1)) who tested 
positive for HCV ribonucleic acid (RNA) or hepatitis C core 
antigen (HCVcAg) in association with positive serology for 
HCV antibody. For the prevalence of current infections, only 
positive RNA or HCVcAg tests are required 
Seroprevalence studies and routine diagnostic tests EMCDDA 
DRID 
indicator 
Recent data 
available 
(2015 or 
later) 
Prevalence of 
hepatitis B infection 
among PWID 
Proportion of current injectors (drug users who have injected in 
the last month, unless otherwise stated (1)) who tested positive 
for hepatitis B surface antigen (HBsAg) 
Seroprevalence studies and routine diagnostic tests 
 
EMCDDA 
DRID 
indicator 
Recent data 
available 
(2015 or 
later) 
(1) Some studies include drug users who have injected illicit drugs in the course of their life (ever injectors). Ever injectors include current injectors and those who do not inject any more. Some studies restrict their definition of 
current injectors to users who have injected in the last 6 months or in the last month. 
(2) A seroprevalence study is based on a protocol with well-defined target population, inclusion criteria, recruitment setting, sampling method and sample size 
(http://www.emcdda.europa.eu/attachements.cfm/att_220260_EN_DRID_module_study_methods_final.pdf). Settings where study participants are recruited are usually low-threshold services (e.g. needle exchange 
programmes), drug treatment centres or prisons. Sampling methods can be systematic or based on respondent-driven sampling methodologies. 
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TABLE 2  
Inputs (national policies), viral hepatitis elimination barometer for PWID 
Area Indicator Definition Methods Data sources Related 2020 
target 
2.
 I
np
ut
s 
—
 
po
lic
y 
Adoption of viral 
hepatitis 
national policy 
inclusive of 
PWID 
Inclusive hepatitis policies are defined as national strategies, 
programmes or action plans (including those integrated into 
broader health strategies or plans) in which people who 
inject drugs are considered an important target group and/or 
specifically mentioned 
Between February and October 2017, a targeted search for policy 
documents was undertaken in the reports submitted by national 
focal points to the EMCDDA, published and grey literature, and 
relevant national websites. Additional information was gathered 
through the EMCDDA DRID network. Where no national HCV 
strategies, programmes and action plans were identified, current 
clinical guidelines were considered. An assessment of if and how 
national policies or clinical guidelines address access for people 
who inject drugs to HCV care and treatment was made, and 
analytical summaries as well as lists of national policy-relevant 
documents were compiled. These were submitted to EMCDDA 
focal points in early 2018 for validation and, if necessary, updated 
up to the last quarter of 2018 
Nielsen, 
2018  
Policy adopted 
 
TABLE 3  
Prevention, viral hepatitis elimination barometer for PWID 
Area Indicator Definition Methods Data sources Related 
2020 target 
3.
 P
re
ve
nt
io
n 
Sterile 
needle/syringe 
distribution 
Number of sterile needles/syringes distributed in a year per 
person who injects drugs. For the needle/syringe coverage 
indicator, a person who injects drugs is defined as a person 
aged between 15 and 64 years who has injected any 
psychoactive substance(s) not according to medical 
prescription in the last 12 months (2017 or most recent year) 
Numerator: Member States report information on the total 
number of syringes provided annually at different types of needle 
and syringe programme sites 
 
Denominator: the latest estimated number of PWID, as 
described in Table 1 
 
EMCDDA harm 
reduction indicator 
 
EMCDDA PDU 
indicator 
200 per person 
who injects drugs 
(WHO, 2017a) 
Opioid substitution 
treatment coverage 
 
Proportion (expressed as a percentage) of people in need of 
opioid-related treatment who are receiving opioid substitution 
treatment in a given year (2017 or most recent year) 
Divide the number of patients receiving opioid substitution 
treatment (OST) in a given year by the estimated number of 
high-risk opioid users (HROU) in that year or the most recent 
data available (with a maximum of 4 years difference between 
the two data points). Add ‘stable’ OST patients if this group is not 
already included in HROU. This indicator is not restricted to 
PWID but provides a proxy for access to OST among opioid 
users, irrespective of the mode of administration 
EMCDDA availability 
and access to 
treatment indicator 
 
EMCDDA PDU 
indicator 
40 % (WHO, 
2017a) 
HBV vaccination 
available in prisons 
 
Existence of a vaccination programme that provided access 
to HBV vaccination to people in prisons in 2016-17 
The information on HBV vaccination programmes in prison was 
obtained from the EMCDDA workbooks and/or ad hoc 
information requests made to the DRID network and from WHO 
Europe factsheets on health in prison (WHO, 2019) 
 
EMCDDA harms 
and harm reduction 
workbook; EMCDDA 
prison workbook; 
WHO, 2019 
HBV vaccination 
available to people 
in prison 
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TABLE 4  
Testing and access to treatment, viral hepatitis elimination barometer for PWID 
Area Indicator Definition Methods Data sources Related 2020 
target 
4.
 T
es
tin
g 
an
d 
ac
ce
ss
 to
 tr
ea
tm
en
t 
HCV diagnostic test 
availability in harm 
reduction services 
 
Hepatitis C tests offered by any harm reduction service in 
the country in 2018.  
Online survey was developed and conducted by partners in the EU 
Joint Action on HIV and Co-infection Prevention and Harm 
Reduction (HA-REACT), with substantial input from the Correlation 
Network (Pericàs et al., 2019) 
Pericàs et al., 
2019 
 
 
Testing available in 
harm reduction 
services 
HCV and HBV 
diagnostic test 
availability in prison 
Existence of national programmes that routinely offer HBV 
and HCV diagnostic tests free of charge to PWID in prisons 
in 2018 
Information collected through the EMCDDA workbooks and/or ad 
hoc information requests made to the DRID network 
EMCDDA harms 
and harm 
reduction 
workbook; 
EMCDDA prison 
workbook 
Testing routinely 
offered to people in 
prison 
Proportion of PWID 
who were tested for 
HCV in the last year 
 
 
 
 
Proportion of PWID (drug users who have injected in the last 
12 months, unless otherwise stated (1)), who reported an 
HCV test in the last 12 months 
Surveys conducted among PWID. In some cases, seroprevalence 
studies are combined with the collection of behavioural data. Some 
studies exclude PWID who are known to be chronically infected 
with HCV. In this case, the denominator is PWID with unknown 
HCV infection status 
 
European countries systematically collect data on people entering 
drug treatment through the TDI, including on HCV tests done in the 
last 12 months 
EMCDDA DRID 
indicator 
 
EMCDDA TDI 
50 % of all people 
with chronic HCV or 
HBV to be 
diagnosed and 
aware of their 
condition (WHO, 
2017a) 
 
Number of newly 
notified acute and 
chronic HCV and 
HBV cases 
attributed to injecting 
drug use 
ECDC case definitions (ECDC, 2018a, 2018b) 
 
ECDC notification system for 2017 (ECDC, 2018a, 2018b) The ECDC 
European 
Surveillance 
System (TESSy) 
Recent data 
available (2017) 
Access to direct-
acting antiviral 
(DAA) treatment for 
PWID with HCV 
infection 
Absence of clinical and reimbursement restrictions for DAA 
treatment for PWID in 2018 
For countries with no inclusive hepatitis national policy, national 
experts were contacted to assess the presence of restrictive 
clinical guidelines for DAA initiation for PWID. They were assessed 
in early 2018 for validation and, if necessary, updated 
 
From Marshall et al. (2018): ‘Restrictions meant that individuals 
with drug or alcohol use dependencies needed to fulfil further 
criteria before being eligible for DAA reimbursement.’ 
 
Nielsen, 
2018. 
Marshall et al., 
2018 
No restrictions on 
treatment access 
related to drug use 
to allow for 75 % 
treatment coverage 
for PWID diagnosed 
with chronic HCV 
infection (2) 
 
(1) Some studies include drug users who have injected illicit drugs in the course of their life (ever injectors). Ever injectors include current injectors and those who do not inject any more. Some 
studies restrict their definition of current injectors to users who have injected in the last 6 months or in the last month. 
(2) The quantifiable 2020 WHO target is 75 % treatment coverage of people who are eligible for treatment and diagnosed with HBV and HCV infections (WHO, 2017a). 
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TABLE 5 
Impact, viral hepatitis elimination barometer for PWID 
Area Indicator Definition Methods Data sources 2020 target 
5.
 I
m
pa
ct
 Prevalence of 
hepatitis C 
antibodies among 
young and new 
injectors (proxy for 
incidence) 
compared with 2015 
baseline 
 
Proportion of current injectors (drug users who have injected 
in the last 12 months, unless otherwise stated (1)) aged less 
than 25 years who tested positive for antibodies to HCV 
 
Proportion of current injectors who have injected for less 
than 2 years who tested positive for antibodies to HCV 
Seroprevalence studies (2) designed to obtain information on the 
prevalence of HCV biomarkers among PWID 
 
Routine diagnostic tests, where the positivity rate (the proportion of 
people testing positive among all people tested in a given period) 
is obtained from routine screening and diagnostic tests done by 
health services 
 
Baseline year: 2015 
EMCDDA DRID 
indicator 
 
30 % reduction in 
new cases 
compared with 
2015 (WHO, 
2017a) 
(1) Some studies include drug users who have injected illicit drugs in the course of their life (ever injectors). Ever injectors include current injectors and those who do not inject any more. Some 
studies restrict their definition of current injectors to users who have injected in the last 6 months or in the last month. 
(2) A seroprevalence study is based on a protocol with well-defined target population, inclusion criteria, recruitment setting, sampling method and sample size 
(http://www.emcdda.europa.eu/attachements.cfm/att_220260_EN_DRID_module_study_methods_final.pdf). Settings where study participants are recruited are usually low-threshold services (e.g. 
needle exchange programmes), drug treatment centres or prisons. The sampling method can be systematic or based on respondent-driven sampling methodologies. 
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Results 
1. Context and need 
Number of injectors among people entering drug treatment 
Based on data collected from drug treatment centres on patients entering drug treatment across the 
EU, Norway and Turkey in 2017, there were at least 53 334 patients who reported injecting any drug in 
the last year. People who injected their primary drug represented 13 % of all treatment entrants 
(ranging from 1 % in the Netherlands to 75 % in Lithuania). The absolute number of current injectors 
entering treatment varied across countries (Figure 2), with the United Kingdom, Italy and Germany 
together contributing to 61 % of the total number of PWID entering drug treatment (see Annex 1). The 
incidence of PWID entering drug treatment per 100 000 population aged 15-64 years was highest in 
the United Kingdom, Ireland, Finland and Luxembourg (Figure 2). This indicator reflects the inflow of 
PWID accessing drug treatment, which is influenced by drug treatment availability and accessibility, 
coverage of the surveillance system and pattern of drug use among treatment entrants. It is likely to 
represent a small proportion of the overall prevalence of injecting drug use, which is usually estimated 
through indirect statistical methods. 
FIGURE 2 
Number and incidence of patients entering drug treatment who reported injecting in the last 
12 months per 100 000 population aged 15-64 years, by country, 2017 
 
Note: Data for Spain and Estonia are for 2016; data for the Netherlands are for 2015. 
Source: EMCDDA 
Prevalence of injecting drug use 
The prevalence of injecting drug use, defined as the proportion of the population aged 15-64 years 
that has injected illicit drugs in the last 12 months, is measured through indirect statistical methods 
such as capture-recapture studies (Raag et al., 2019) and treatment multiplier studies (Larney et al., 
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2017) and comes with a high degree of uncertainty. In the 15 national studies conducted from 2015 
onwards, the estimated prevalence of injecting drug use ranged from less than 1 per 1 000 in Cyprus, 
the Netherlands and Spain to more than 5 per 1 000 in Czechia, Estonia and Latvia (Figure 3). 
Absolute numbers and prevalence by country are shown in Annex 1. 
FIGURE 3 
Estimated prevalence of injecting drug use in EU Member States and Norway, 2015-17 
 
Source: EMCDDA. 
Main drugs injected 
Heroin and other opioids remain overall the most commonly injected drugs among drug treatment 
entrants (Annex 2), with the exception of Czechia (methamphetamine) and Norway (amphetamine). 
Reports from low-threshold services suggest that stimulants are also commonly injected in France 
(cocaine), Hungary (synthetic cathinones), Latvia (amphetamine) and Luxembourg (cocaine). In 2017, 
the European Syringe Collection and Analysis Project Enterprise (ESCAPE) obtained information on 
injected substances by analysing in laboratories the residual content of used syringes from collection 
sites in six cities (Amsterdam, Budapest, Glasgow, Helsinki, Lausanne and Paris) (EMCDDA, 2019). 
A high proportion of syringes from all six cities were found to contain stimulants, which may indicate a 
high prevalence of stimulant use among people who inject drugs. This has potentially important 
implications, since stimulant injecting has been associated with higher-risk injecting practices and HIV 
outbreaks (Arendt et al., 2019; Giese et al., 2015; McAuley et al., 2019). 
Prevalence of needle/syringe sharing 
The main risk factor for blood-borne infections is the sharing of needles, syringes and other drug 
equipment. In recent national or local biological and behavioural surveillance studies, the proportion of 
people who inject drugs reporting sharing used needles/syringes in the last 4 weeks was 47 % in 
Bulgaria (National Centre for Addictions, 2017), 40 % in Romania (National Antidrug Agency, 2016) 
and 39 % in Hungary (Dudás et al., 2015) (Annex 2). Under the treatment demand indicator (TDI) 
protocol, those entering specialised drug treatment who report drug injecting are asked about their 
sharing of used needles/syringes in the last 4 weeks. The data available for 17 countries in 2017 
suggest that, in eight countries, more than 10 % of all treatment entrants who report injecting drugs 
have recently shared a needle or syringe (Figure 4). It is important to note that people reporting drug 
injection on treatment entry may not be representative of all people who inject drugs, and those not in 
contact with services may have even higher levels of drug use and injecting. 
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FIGURE 4 
Self-reported sharing of needles or syringes among people entering drug treatment who report 
injecting drugs, 2017 
 
Note: Sample size per country is shown in parentheses. Data for Spain are for 2016. 
Source: EMCDDA. 
Prevalence of HCV infection among PWID 
The prevalence of antibodies to HCV (anti-HCV) among people who inject drugs — indicating chronic 
or past infection (past infection either naturally cleared or treated) — is estimated from 
seroprevalence studies or from the results of routine diagnostic testing in drug treatment centres or by 
low-threshold services (Annex 3). In 2016-17, anti-HCV prevalence among people who inject drugs 
varied from 15 % to 82 %. In 8 out of the 14 countries with national data, more than half of people 
who inject drugs have been infected with HCV (Figure 5). 
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FIGURE 5 
HCV antibody prevalence (%) among people who inject drugs: results from seroprevalence 
studies and diagnostic tests with national and sub-national coverage, 2016-17 
 
Source: EMCDDA. 
Some countries also report the prevalence of chronic and/or current infections among PWID, using 
HCV ribonucleic acid (RNA) tests to confirm the presence of the virus (Annex 3). Among the four 
countries reporting data on the prevalence of chronic infections (anti-HCV positive and HCV RNA 
positive) among PWID with a sample size greater than 100, the prevalence ranged from 23.1 % in 
Leipzig (Germany, 2011-14) to 55.6 % in Vienna (Austria, 2017) (Table 6 and Annex 3). Among the 
four countries collecting data on the prevalence of all current infections among PWID with a sample 
size greater than 100 (HCV RNA positive, irrespective of anti-HCV status, therefore including acute as 
well as chronic infections), the prevalence ranged from 26.7 % in England and Wales (United 
Kingdom, 2017) to 65.1 % in Vienna (Austria, 2017) (Table 6). 
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TABLE 6 
Prevalence of chronic HCV infection among PWID, EU Member States, 2014-2017 
Country Region/city Year Study 
type 
Setting Case definition 
of injectors 
Sample 
size 
% HCV 
antibody 
positive 
among all 
% HCV RNA 
positive and 
HCV antibody 
positive 
among all 
(chronic 
infections) 
% HCV RNA 
positive 
among all 
(current 
infection) 
Austria Graz (Marienambulanz) 2017 DT LTS Current (not 
specified) 
68 82.4 35.3 35.3 
Vienna 2017 DT DTC, NSP, LTS Ever 315 83.5 55.6 65.1 
Vorarlberg/Lukasfeld 2017 DT DTC Ever 50 60.0 36.0  
Greece National 2017 DT DTC, LTS, PRI Ever 101   50.5 
Attica 2017 DT DTC, LTS, PRI Ever 100   51.0 
Luxembourg National 2017 DT DTC, NSP, PRI, STI Ever 66 75.8 53.0  
United 
Kingdom 
UAM England and 
Wales 
2017 SP DTC, NSP, LTS Ever 2584 52.2 25.7 26.7 
UAM Northern Ireland 2017 SP DTC, NSP, LTS Ever 71 22.5 8.5 8.6 
Germany Berlin 2011-14 SP RDS Last 12 months 337 53.7 37.1 38.3 
Essen 2011-14 SP RDS Last 12 months 197 71.1 45.2 46.7 
Leipzig 2011-14 SP RDS Last 12 months 130 36.9 23.1 28.5 
Frankfurt 2011-14 SP RDS Last 12 months 285 64.6 50.2 51.9 
Cologne 2011-14 SP RDS Last 12 months 322 66.5 47.5 52.2 
Hanover 2011-14 SP RDS Last 12 months 252 73.0 54.0 56.0 
Munich 2011-14 SP RDS Last 12 months 235 62.6 36.2 37.0 
Hamburg 2011-14 SP RDS Last 12 months 319 67.7 44.8 46.7 
Note: SP:seroprevalence study, DT, diagnostic test; DTC, drug treatment  centre; LTS, low-threshold services; NSP, needle and syringe programme; PRI, prison;  RDS, respondent-driven sampling; 
STI, Sexually Transmitted Infections Clinics; UAM, unlinked anonymous monitoring. 
Sources: EMCDDA; Wenz et al., 2016.
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Prevalence of HBV infection among PWID 
Among drug users, HBV infection is less common than HCV infection, but is still higher than in the 
general population, despite the availability of an effective vaccine, which is included in the 
recommended vaccination schedules in most EU Member States (ECDC, 2018c). For this virus, the 
presence of the HBV surface antigen (HBsAg) indicates a current infection, which may be recent or 
chronic. In the seven countries with national data for 2016-17, the prevalence of current HBV 
infections among PWID ranged from 1.4 % (in Latvia) to 9.4 % (in Spain) (Figure 6 and Annex 3). 
FIGURE 6 
HBV surface antigen prevalence (%) among people who inject drugs: results from 
seroprevalence studies and diagnostic tests with national and subnational coverage, 2016-17 
 
Source: EMCDDA 
Case studies on estimating the prevalence of HCV and HBV among PWID 
Seroprevalence studies versus routine diagnostic tests in Latvia 
Latvia estimated the prevalence of HCV antibodies and HBsAg among PWID through two sources: 
the Drug Users Cohort Study (RDUCS) (Ķīvīte et al., 2017) and needle and syringe programmes 
(NSPs) offering routine testing to clients. The RDUCS was started in Riga in 2006, and in 2017 it 
covered five cities and included 550 current injectors. Seroprevalence results since 2012 indicate that 
between 83.3 % and 85.0 % of participants have been exposed to HCV (85.2 % in 2017) and that 
between 2.4 % and 3.8 % are currently infected with HBV (3.6 % in 2017). Over the same period, the 
annual positivity rate of HCV antibody tests offered to clients of NSPs (data from 12-20 NSP services 
screening 427-1 031 clients) ranged from 52 % to 74 % (57 % in 2017). The annual positivity rate for 
HBsAg tests (562-1 055 clients screened) ranged from 1 % to 3 % (1 % in 2017). 
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Initial recruitment into the cohort study was based on respondent-driven sampling at street level in 
2006. In 2017, the proportion of participants who reported using drug treatment services within the 
last year was 5.1 %. The cohort study therefore reflects the prevalence of infection among people 
who are at higher risk: they have injected for several years with a low level of access to drug services. 
Estimates from rapid tests done in low-threshold services (e.g. through NSPs), on the other hand, 
may be biased towards a population of users with more access to health services and exclude users 
who already know their positive status, which could lead to underestimation of the true prevalence of 
infection. Estimates derived from annual diagnostic tests (as opposed to observational studies) have 
the advantage of being systematically collected every year and are based on larger sample sizes. 
Introducing HCV RNA testing in routine surveys among PWID in the United Kingdom 
After an acute infection, 25-30 % of those infected naturally clear the virus. Patients who have 
successfully been treated also clear the virus. Those who naturally clear the virus and those who are 
successfully cured will, however, still test positive for HCV antibodies. Individuals who remain 
chronically infected are at risk of cirrhosis and cancer, and they can transmit the virus to others when 
sharing any injecting material that has been in contact with their blood. As more patients gain access 
to direct-acting antiviral (DAA) treatment, monitoring should aim to measure the prevalence of chronic 
infections. This requires tests for HCV RNA or HCV core antigen, in association with antibody tests. 
In the United Kingdom, Public Heath England collects information on a sample of 2 500-3 500 former 
and current injectors every year using the unlinked anonymous monitoring (UAM) survey 
methodology (Public Health England, 2018). The survey combines a questionnaire with the collection 
of dried blood spots for the detection of HIV, HBV and HCV antibodies and, since 2016, HCV RNA. 
Combining HCV RNA tests with antibody tests allows the survey to distinguish recent infections 
(antibody negative and RNA positive) from chronic infections (antibody positive and RNA positive) 
and past (resolved) infections (antibody positive and RNA negative). Among the 2 655 former and 
current injectors included in the 2017 survey, 51 % tested positive for HCV antibodies. Among these, 
49 % tested positive for HCV RNA and could be classified as having a chronic infection (25 % of the 
total). Of the total, 26 % had a past infection and less than 1 % had a recent infection. The rest (48 %) 
were negative on both tests (Figure 7). 
In addition to providing useful data on the prevalence of chronic and recent infections, the UAM 
survey provides information on the proportion of PWID who are aware of their HCV status.  
FIGURE 7 
HCV antibody prevalence over time and introduction (2017) of HCV RNA test in the UAM 
survey among PWID in England, Wales and Northern Ireland, 1998-2017 
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Source: UAM survey of PWID, Public Health England, 2018. 
 
2. Inputs 
Hepatitis national policy 
The ‘inputs’ building block of the elimination barometer provides information on the existence of an 
official national viral hepatitis policy or action plan where PWID are considered an important target 
group or specifically mentioned, which constitutes an important step towards the implementation of a 
sustainable elimination strategy. By the last quarter of 2018, 18 EU Member States and Norway had 
national HCV policies in place and such policies were in preparation in Austria, Czechia, Hungary, 
Poland and Romania (Figure 8 and Annex 4). In 13 countries, HCV policies had been adopted or 
renewed since 2015 (Nielsen, 2018). 
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FIGURE 8 
Countries with a viral hepatitis policy inclusive of PWID, EU Member States and Norway, 2018 
 
Source: EMCDDA 
 
Case study on national hepatitis policy 
Adopting a new national strategy for the elimination of HCV in Malta 
Malta has endorsed the Sao Paulo declaration on viral hepatitis, committing to take a broad and 
coordinated approach to support the implementation of the core interventions outlined in the WHO 
global health strategy. 
In March 2018, a national strategy for the elimination of HCV was adopted by the Ministry of Health 
after a 30-day public consultation period. The vision is to achieve a situation where transmission of 
HCV is halted in Malta — and everyone living with HCV has access to safe, affordable and effective 
prevention, testing, care and treatment services — by 2025. 
The preventive section of the strategy will focus on all modes of transmission, including injecting drug 
use. This will entail revising the current needle and syringes programme and improving prevention 
and harm reduction measures for users of stimulants (cocaine and new psychoactive substances) 
and PWID who are not in contact with treatment services. The screening and diagnosis section of the 
strategy will target key populations, with opioid substitution treatment (OST) patients being one of the 
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priority groups. Currently, HCV treatment is offered to patients who have an advanced stage of 
fibrosis (a Metavir score of F4) and who are in contact with the hospital system. The plan is to extend 
access to DAA treatment to patients who have less advanced fibrosis. Being a current injector is not a 
barrier to treatment access, but there have been cases of treatment being restricted when adherence 
was expected to be low. The drug treatment centres at the Foundation for Social Welfare Services will 
contribute to the elimination of HCV by training staff in the diagnosis of HCV among drug users, by 
facilitating referral of patients for treatment initiation, by reducing the time lag between first 
appointments and initiation of DAA treatment and by following up diagnosed drug users who have 
difficulties in going to appointments to increase their access to care. 
 
3. Prevention 
Prevention is the next key building block of the barometer. There is an effective vaccine against HBV, 
and the combination of high levels of needle exchange coverage and opioid substitution treatment is a 
cost-effective intervention to reduce the risk of blood-borne infections among PWID (Platt et al., 
2017). Prevention and harm reduction measures are therefore key interventions for progressing 
towards the elimination of viral hepatitis among PWID, since they prevent new infections but also 
provide an opportunity to reach out to high-risk populations for testing to link them to care. 
Needle and syringe programme coverage 
National-level data on the coverage of needle and syringe programmes are available for 16 countries, 
with only four of these (Estonia, Finland, Luxembourg and Norway) providing a level of coverage that 
is above the 2020 target of 200 syringes per injecting drug user (Figure 9 and Annex 4). 
FIGURE 9 
Coverage of specialised syringe programmes: estimated number of syringes provided per 
person who injects drugs in 2017, EU Member States and Norway
 
Source: EMCDDA 
Opioid substitution treatment coverage 
The coverage of opioid substitution treatment is estimated to be at or above the 2020 WHO target of 
40 % in 11 of the 18 EU countries for which estimates of the population of high-risk opioid users are 
available (Figure 10 and Annex 4). In the EU as a whole, about half of high-risk opioid users receive 
substitution treatment. In those countries for which data for 2007 or 2008 are available for 
comparison, there was generally an increase in coverage between 2007 or 2008 and 2017. Levels of 
provision, however, remained low in seven countries providing coverage. 
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FIGURE 10 
Coverage of opioid substitution treatment in 2017 or most recent year and in 2007 or 2008 
(showing percentage of estimated high-risk opioid users receiving treatment and the 
uncertainty interval)  
 
Source: EMCDDA 
Hepatitis B vaccination availability in prison 
Because of the high prevalence of HBV infection and drug use among people in prisons, and based 
on available evidence regarding the implementation of HBV vaccination in prison settings, it is 
advisable to offer HBV vaccination to people in prison. It is recommended that HBV vaccination be 
offered at entrance to all individuals with no vaccination history or an unknown vaccination history 
and/or negative serology, to avoid further transmission within the prison setting (ECDC and EMCDDA, 
2018a). 
In 2017, hepatitis B vaccination was available to people in prison in 23 countries in the EU and 
Norway (Annex 4). There was no HBV vaccination programme for people in prison in Bulgaria, 
Czechia, Latvia, Lithuania or Romania. When available, the ways in which vaccination was offered 
varied by country. For example, it was offered to all eligible prisoners in Ireland, Spain, France, Italy, 
Malta, Portugal, Finland, Sweden and the United Kingdom. In Belgium, Denmark, Croatia, Slovenia 
and Slovakia it was available to prisoners on request (on an opt-in basis). In Poland, it was available 
only if requested by a physician (WHO, 2019). 
Data on HBV vaccination coverage among PWID are scarce. A study undertaken in Poland in 2017 
among a sample of 179 PWID showed that 26.8 % reported being vaccinated against HBV (36.7 % 
reported being unvaccinated, while the others did not recall their status) (information provided by 
Polish focal point). Data from PWID entering drug-related treatment in Greece in 2017 showed that 
29.3 % of clients had been vaccinated against HBV. Coverage was higher among women, those who 
had been injecting for more than 2 years and those with no history of incarceration (information 
provided by Greek focal point). 
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Case study on prevention measures 
Harm reduction coverage in Czechia 
In December 2018, a national policy for the elimination of viral hepatitis in Czechia was still in 
preparation, but prevention and harm reduction measures targeting PWID were already in place. In 
2017, the majority of the estimated 43 700 PWID in the country were injecting methamphetamine. The 
latest HCV prevalence estimate among injectors — based on the results of HCV antibody rapid tests 
offered to 1 720 injectors at 63 low-threshold services in 2017 — was 15.9 %, which is lower than the 
EU average. However, this is likely to be an underestimation of the true prevalence since injectors 
who already know their positive status and have not received treatment are less likely to be retested. 
Nine of the 1 113 PWID tested (0.8 %) in 2017 for HBV were reactive to HBsAg. A multicentre 
seroprevalence study is being conducted in 2018 to complement the data from routine diagnostic 
tests. 
HBV vaccination, with a mandatory three doses, was included in 2001 in the national vaccine 
schedule, for children at 3, 5 and 11-13 months of age. Susceptible adults from specific at-risk groups 
(nurses, outreach workers) with no history of vaccination can be vaccinated as well. Although 
vaccination is offered free of cost to patients at some hepatology and infectious disease centres, there 
is no systematic strategy for vaccinating PWID. HBV vaccination is not currently offered in prisons. 
In 2017, the 108 NSP services in Czechia distributed 6 401 662 needles and syringes (Figure 11). 
The network of low-threshold agencies involved in the distribution of safe injecting material includes 
54 drop-in centres and the same number of outreach programmes. There are no NSPs in prisons. In 
addition to distributing needles and syringes, these agencies provide materials to promote alternatives 
to injecting (gelatine capsules, foil, snorting tubes), condoms and information on the prevention of 
blood-borne infections through leaflets and face-to-face counselling. Together, they reach an 
estimated 70-80 % of high-risk drug users in the country. The estimated number of sterile needles 
and syringes per person who injects drugs in 2017 was 147, which remains below the target of 200 
set by WHO Europe for 2020. 
FIGURE 11 
Estimated numbers of PWID and numbers of sterile needles and syringes distributed in 
Czechia, 2005-2017 
 
Source: Czech focal point. 
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The opioid substitution medications prescribed in Czechia are methadone (30 %) and buprenorphine 
(70 %) (mono-preparation or with naloxone). Buprenorphine can be prescribed by any medical doctor 
in a strict prescription regime. In Czechia in 2017, most of the 13 100 high-risk opioid users were 
misusing buprenorphine through injection. In the same year, there were an estimated 5 000 patients 
on OST. This indicates that 38 % of high-risk opioid users were on OST, just below the 2020 WHO 
target for opioid-dependent PWID (40 %). 
 
4. Testing and linkage to care 
To eliminate viral hepatitis as a public health threat, the WHO target aims for 50 % of people who are 
chronically infected with viral hepatitis to be diagnosed and 75 % of eligible patients to be receiving 
treatment by 2020. Yet many infections still go undiagnosed and untreated in people who inject drugs. 
Diagnostic test availability in harm reduction services and prisons 
Published public health guidance on integrated HIV, HBV and HCV testing stresses the importance of 
adopting an integrated approach to the three viruses, which have common modes of transmission and 
risk groups, to maximise synergies and reduce costs (ECDC, 2018c). WHO guidelines on HBV and 
HCV testing provide recommendations on the type of diagnostic tests to be used, including summary 
algorithms for diagnosis, treatment and monitoring of chronic HBV and HCV infections (WHO, 2017b). 
The ‘5Cs’ principle defined by WHO applies to all models of testing and in all settings: consent, 
confidentiality, counselling, correct test results and connection (linkage to prevention, treatment and 
care services). 
Harm reduction services and prisons are appropriate settings to reach and offer infectious disease 
screening to a large number of drug users. In a survey conducted in 2017 among harm reduction 
service providers by the EU Joint Action on HIV and Co-infection Prevention and Harm Reduction 
(HA-REACT), in collaboration with the Correlation Network, services providers from 22 EU Member 
States reported that at least some harm reduction services offered HCV testing to drug users (Pericàs 
et al., 2019) (Annex 5). Although some infectious disease testing was reported to be offered in the 
prison system in 26 European countries in 2018, HCV and HBV tests were reported to be routinely 
offered to people in prison in only 19 countries (Annex 5). 
Proportion of PWID tested for HCV in the last year 
The availability of HCV and HBV testing in drug services and in prisons is crucial, but it may not 
always translate into actual testing. In some of the injecting drug use prevalence studies described 
earlier, investigators also looked at HCV tests done in the previous 12 months. In recent European 
studies, the proportion of people who inject drugs who reported having been tested in the last 
12 months (excluding those who knew their positive status) ranged from 7 % in Romania (National 
Antidrug Agency, 2016) to 66 % in France (Cadet-Taïrou et al., 2018). As part of the EMCDDA TDI 
protocol, treatment entrants who report injecting drugs are asked about previous HCV tests. In 9 
countries out of 14 with data for 2017, less than half of those who entered drug treatment had been 
tested over the last 12 months (Figure 12 and Annex 5). The percentage exceeded 50 % only in 
Spain, Czechia, Austria, Bulgaria and Luxembourg. 
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FIGURE 12 
Self-reported history of HCV testing among people entering drug treatment reporting injecting 
drugs, by country, 2017 
 
 
Note: Sample size per country is shown in parentheses. Data are for 2017, except for Spain (2016). 
Source: EMCDDA. 
Newly notified HCV and HBV cases attributed to injecting drug use 
EU Member States report newly diagnosed cases of hepatitis C or B infection using the EU 2012 case 
definitions. The EU case definitions are based on laboratory criteria and differentiate acute from 
chronic cases (ECDC, 2019a, 2019b). When the information is available, the most likely route of 
transmission is also reported. A case attributed to injecting drug use might be diagnosed in a person 
who does not inject anymore, so the information refers to ever injectors (people who have injected 
drugs at some point in their life) rather than current injectors. The completeness of surveillance data 
and the availability of information on transmission route varies by country (ECDC, 2019c). Overall, in 
2017, information on the most likely route of transmission was available for 27 % of newly notified 
hepatitis C cases and for 18 % of newly notified hepatitis B cases in the EU and Norway. 
While the reporting of acute cases may help to detect outbreaks and provide information on 
incidence, in countries with relatively high completeness of transmission route data the absolute 
number of newly notified chronic cases attributed to injecting drug use (Annex 6) and the incidence of 
new notifications of chronic cases attributed to injecting drug use per 1 000 PWID can also provide 
information on testing activity targeting this group (although these figures do not tell us anything about 
the total number of PWID tested in a given year). For instance, in 2017, Sweden had a completeness 
rate of 59 % and 26 % for the information on the transmission route of all newly notified HCV and 
HBV cases, respectively. It notified 589 chronic HCV cases linked to injecting drug use, 
corresponding to a notification rate of 73 cases per 1 000 PWID. In the same year, Sweden notified 
13 chronic HBV cases linked to injecting drug use, corresponding to a notification rate of 1.6 per 
1 000 PWID (Figure 13). 
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FIGURE 13 
Notifications of acute and chronic HCV and HBV cases with injecting drug use as the likely 
transmission mode, by country, 2017: (a) absolute number, (b) per 1 000 PWID 
a. HCV a. HBV 
 
 
b. HCV b. HBV 
 
 
Note: Data are shown for countries reporting chronic or undocumented stage infections with an overall data completeness of 
> 25 % for the mode of transmission and with recent PWID population estimates available. 
Sources: ECDC and EMCDDA. 
In 2017, a total of 3 600 newly notified hepatitis C cases attributed to injecting drug use were reported 
by 20 EU Member States and Norway. Of these, 1 305 were classified as chronic cases, 178 were 
classified as acute cases and for 2 117 no information was available on the disease stage. In cases 
for which information on the transmission mode was available, injecting drug use was reported as the 
likely cause for 40 % (178 out of 445) of all acute HCV cases and 55 % (1 305 out of 2 363) of all 
chronic HCV cases (ECDC, 2019b). 
In the same year, 168 newly notified hepatitis B cases attributed to injecting drug use were reported 
by 16 EU Member States and Norway. Of these, 60 were classified as chronic cases, 68 were 
classified as acute cases and for 40 no information was available on the infection stage. For HBV 
infection, an estimated 11 % (68 out of 599) of all acute cases and 3 % (60 out of 1 823) of all chronic 
cases for which information on the transmission mode was reported in 2017 in the EU and Norway 
were linked to injecting drug use (ECDC, 2019a). 
Access to antiviral treatment for PWID 
The available HBC and HCV treatments are as effective in people who inject drugs as in other 
groups, especially when psychological and adherence support are offered (UNODC, 2017). For 
chronic HBV infection, although treatment often requires lifelong administration, the development of 
nucleoside/nucleotide’analogues with low rates of resistance has provided improved treatment 
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options for patients (Bhattacharya and Thio, 2010). For chronic HCV, DAAs are an effective treatment 
option for people who are chronically infected with the virus, including current injecting drug users 
(Grebely et al., 2018). The goals of DAA therapy are to cure HCV infection in order to prevent 
complications and mortality, improve quality of life, remove stigma and prevent onward transmission 
of HCV. WHO recommends offering treatment to all individuals diagnosed with HCV infection who are 
12 years of age or older (with the exception of pregnant women), irrespective of disease stage (WHO, 
2018). The WHO guidelines also stress that treating people who inject drugs alongside the provision 
of harm reduction interventions (to reduce the risk of reinfection) is cost-effective, despite the fact that 
DAAs remain expensive in many high-income and upper-middle-income countries. Testing and 
linkage to treatment for infected PWID are therefore core components of the elimination strategy: in 
addition to the direct beneficial impact on the treated individual, treatment has the potential to reduce 
transmission in the community (treatment as prevention). The indirect benefits of treatment are 
increased when the risk of reinfection is reduced (in low-prevalence settings or in settings with a high 
coverage of harm reduction measures such as NSPs and OST). 
In spring 2018, in 8 of the 11 EU Member States without an HCV policy, clinical guidelines still 
restricted access to HCV treatment for people who inject drugs (Nielsen, 2018), and five EU Member 
States restricted DAA reimbursement for patients with drug or alcohol dependencies (Marshall et al., 
2018) (Annex 6). 
 
Case studies on testing and linkage to care 
HCV testing among PWID in drug treatment in Belgium 
The Belgian public health institute, Sciensano, estimated the number and percentage of PWID in 
treatment for substance use disorders between 2011 and 2014 who had been screened at least once 
for HCV between 2008 and 2015 (Van Baelen et al., 2019). They obtained this information by linking 
patient records from the TDI to the health insurance databases to identify the number of patients who 
had undergone any type of HCV test (antibody, RNA and/or genotyping). They included a total of 
30 905 patients: 74 % were male, aged 30-39 years; 3.6 % (1 125) were classified as current injectors 
(having injected at least once in the last 30 days); 7.2 % (2 227) were classified as past injectors 
(defined as having injected ever but not in the last 30 days); and 70.5 % (21 796) reported that they 
had never injected. 
Among the 1 125 current injectors who entered treatment during 2011-2014, 973 (86.5 %) had had at 
least one HCV test performed. The percentage among past injectors was 84.7 %. The screening of 
PWID who are not in drug treatment is unknown. Sciensano is currently doing a study in Brussels 
using respondent-driven sampling and capture-recapture methods to estimate the number of PWID 
and the prevalence of HCV among them. 
Case finding within micro-elimination of HCV in the Netherlands 
In 2017, there were an estimated 23 000 people aged 18 years or older chronically infected with HCV 
in the Netherlands (Koopsen et al., 2018). Of these, 15 % (3 434) were ever injectors. In 2014, 450 
deaths were related to viral hepatitis. Modelling work showed that a scenario where diagnosis, 
eligibility and HCV DAA treatment uptake were gradually increased (to reach 890 diagnosed patients 
annually by 2016 and a treatment uptake of 1 700 annually by 2018) would be the most realistic 
strategy for achieving a 65 % reduction in liver-related deaths in the Netherlands by 2030 (Willemse 
et al., 2015). 
In 2016, two key documents translated this scenario into policy: the Health Council’s advice on 
hepatitis screening (Health Council of the Netherlands, 2016) and the national hepatitis plan (David et 
al., 2016). The national plan details five crucial steps towards elimination. The second step stresses 
the importance of identifying chronic carriers in a timely manner through active screening. A 
nationwide HCV awareness campaign, implemented in the Netherlands between September 2009 
and September 2010 and targeting PWID in addiction care, had already shown that a nationwide 
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campaign for awareness and case finding of PWID with HCV was an effective and cost-effective 
intervention (Helsper et al., 2017). 
The Health Council recommended HCV screening for drug users who had ever injected and other risk 
groups. It also recommended that all addiction care centres in the Netherlands should provide 
individual HCV consultations and testing. One challenge for the case-finding strategy will be the 
retrieval of previously diagnosed HCV-infected individuals who are lost to follow-up. In a micro-
elimination initiative in the Utrecht province, 269 patients were traced through laboratory registers and 
invited back into care. After renewed assessment, 42 chronically infected patients were re-identified 
and linked to care; 76 % had a history of injecting drug use (Kracht et al., 2018). 
Extending rapid diagnostic tests to low-threshold services and linking to care in France 
To achieve its declared goal of hepatitis C elimination by 2025, France is implementing three core 
interventions: (1) strengthening prevention through innovative outreach actions to reach priority 
groups and groups with low access to health services, (2) reinforcing local access to screening with 
rapid diagnostic tests in a combined approach to HIV, HCV and HBV, and (3) strengthening access to 
hepatitis C treatment by allowing a wider range of professionals to prescibe treatment.  
In 2018, there were an estimated 110 000 individuals infected with HCV in France. Among these, an 
estimated 69 000 were unaware of their infection and 50 000 were drug users. In order to diagnose 
more PWID and to link them to care, since 2016 rapid diagnostic tests for HCV/HBV/HIV have been 
carried out by trained non-medical personnel in drug treatment centres and low-threshold facilities. A 
practical guide to the improvement of hepatitis C prevention and care in specialised drug treatment 
centres and low-threshold facilities was published in 2018 (Hoareau and Reynaud-Maurupt, 2018). 
The guide details the various complementary screening tools available (rapid diagnostic tests, dried 
blood spot tests, fibroscans), stressing the importance of testing for the three viruses (HCV/HBV/HIV) 
and of offering vaccination in the case of a negative HBV test. It emphasises the importance, when 
offering testing to a drug user, of informing her or him of the care pathways and treatment options, 
and of providing counselling in case of a positive result. Other key recommendations in the guide 
include mobilising the multidisciplinary team in the drug treatment centre; providing testing, 
counselling, treatment and follow-up in one location; and taking into account the specificities of 
particular groups (migrants, prison inmates, men who have sex with men). 
This approach was implemented in the Île-de-France region between October 2016 and December 
2017; 461 patients were diagnosed with a chronic infection, 86 % had a first hepatology consultation 
and 67 % started DAA treatment. 
Cascade of care for HCV infection in Luxembourg 
In Luxembourg, the Institute of Health and the Centre for Infectious Diseases undertook a study of 
295 drug users recruited at the drug consumption room and at three harm reduction agencies 
between November 2015 and December 2017. The aims of the study were to describe the risk-taking 
practices of drug users; to test participants for infectious agents (HCV, HBV, HIV, syphilis), viral load 
and liver markers; to carry out fibroscanning; and to link them to care, in order to document the 
cascade of care for HCV infection and identify barriers to receiving care. 
Of the 295 participants, 71 % were male and 26 % did not have a social security number. The mean 
age was 38.7 years. Eighty-two per cent were current injectors, half of them reporting injecting at least 
once a day. Cocaine use, often associated with heroin use, was reported by 59 % of participants. 
Anti-HCV was detected in 72 % of participants. Among these, 62 % had a detectable HCV viral load. 
Among users with a detectable HCV viral load, 31 % had fibrosis at stage F2 or greater. Half of these 
patients (54 %) returned to the hospital and received DAA treatment, and 82 % had a sustained viral 
response 12 weeks after the end of treatment. 
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Based on this cascade of care (Figure 14), a series of barriers was identified. First, although there is 
no health insurance restriction on current injectors’ access to DAA treatment, clinicians still prioritise 
the treatment of those with fibrosis at a more advanced stage. Second, it usually took 2-3 weeks for 
patients to get the results of the RNA test, which measures viral load. Only half of patients with a 
diagnosis of advanced fibrosis went to their hospital appointment for treatment initiation. One of the 
recommendations following this study was to provide the result of the viral load test and the 
information on eligibility for treatment on the same day, and to offer support with hospital 
appointments. Moreover, DAA treatment is now provided directly at the drug consumption room and 
at other harm reduction centres by a nurse who is responsible for treatment initiation and follow-up of 
patients. DAA treatment for people who inject drugs is also available in prisons and in a homeless 
shelter, and it can be prescribed by medical doctors prescribing opioid substitution treatment. 
FIGURE 14 
Cascade of care for HCV infection in an outreach programme for injecting drug users in 
Luxembourg, 2015-17 
 
Source: Devaux, 2018. 
 
5. Impact 
The elimination of viral hepatitis as a public health threat has been defined as a 90 % reduction in the 
number of new chronic hepatitis B and C infections and a 65 % reduction in the number of deaths by 
2030, with milestones for 2020 set as 30 % and 10 % reductions, respectively (WHO, 2016a). The 
indicators proposed by WHO to monitor the impact include the incidence of HCV and HBV infections 
and the number of deaths from hepatocellular carcinoma, cirrhosis and chronic liver diseases that are 
attributable to HCV and HBV infections (WHO, 2016b). 
 
Although robust surveillance data and observational studies measuring the impact of interventions 
targeting people who inject drugs are currently scarce, mathematical modelling can provide some 
insights into how far we are from reaching the WHO targets for viral hepatitis elimination and what 
remains to be done. A recent study looked at baseline levels of HCV seroprevalence, opioid 
substitution treatment, and needle and syringe programme coverage, and estimated DAA HCV 
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treatment rates among people who inject drugs in 11 European sites (countries and cities) in 2016 
(Fraser et al., 2018). Using a dynamic HCV transmission model among people who inject drugs, it 
assessed the impact by 2026 of various strategies in terms of prevalence and incidence. 
These projections illustrated some important messages. First, they suggested that opioid substitution 
treatment and needle and syringe programmes alone would not be enough to reach the elimination 
targets: a combination of opioid substitution treatment, needle and syringe programmes and HCV 
treatment would be required. Second, while not sufficient in itself, scaling up opioid substitution 
treatment and needle and syringe programmes for people who inject drugs would increase the impact 
of HCV treatment as a prevention strategy and would reduce the number of cases of HCV treatment 
needed to achieve the targets. Third, most of the sites will still require a substantial increase in 
treatment rates in order to reduce incidence to 2 per 100 person-years. The team has also 
undertaken other modelling that shows the importance of treating reinfections and of continuing 
treatment even once elimination targets have been achieved (Fraser et al., 2018). 
Prevalence of hepatitis C antibodies among young and new injectors 
The prevalence of anti-HCV among PWID aged less than 25 years (‘young injectors’) who have been 
injecting for less than 2 years (‘new injectors’) can be used as a crude proxy for incidence (Annex 7). 
Prevalence among this group reflects relatively new transmission (incidence) and it is expected to 
decrease over time as prevention and treatment coverage increases. The point estimate of 
prevalence of HCV antibodies among young injectors found in national or multi-city studies in 2015 
ranged from 14 % in Czechia to 56.5 % in Greece. In 2017, it was 11.5 % in Czechia and 67.4 % in 
Greece (Figure 15a). The prevalence among new injectors found in national or multi-city studies in 
2015 ranged from 8.5 % in Czechia to 34.8 % in Latvia. In 2017, it ranged from 11.5 % in Czechia to 
29.5 % in Turkey (Figure 15b). 
Although some of the estimates are based on a small sample size, they suggest that in 2017 there 
was ongoing transmission of HCV among PWID at levels not significantly different from those in 2015, 
with some countries even reporting higher point estimates in 2017 (Figure 15). 
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FIGURE 15 
HCV antibody prevalence (%) among PWID (a) aged less than 25 years and (b) injecting for 
less than 2 years: results from diagnostic tests and seroprevalence studies with national or 
multi-city coverage, baseline (2014-15) and 2017 
a. PWID aged less than 25 years 
 
b. PWID who have been injecting for less than 2 years 
 
Note: CI, confidence interval. 
Source: EMCDDA. 
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Discussion 
We presented the European overview of the five building blocks of the viral hepatitis elimination 
barometer for PWID. The corresponding data tables are presented in the annexes to this document. 
Using routinely collected quantitative data and complementing them with qualitative information, the 
elimination barometer is a framework that should help Member States to identify data gaps and 
assess how far they are from the elimination targets for HCV and HBV among PWID. 
Limitations 
The data come from a variety of sources (e.g. surveillance data, programme data, observational 
studies, surveys among experts), which all have their strengths and limitations. Although surveillance 
and programme data (e.g. the results of diagnostic tests routinely done in services or the number of 
clean needles and syringes distributed) can provide useful information on a phenomenon or an 
intervention over time, they are prone to selection bias and low completeness. Although observational 
studies (e.g. cross-sectional sero-behavioural studies using respondent-driven sampling) are 
designed to recruit representative samples of drug users, they are resource-intensive and can be 
based on small sample sizes, leading to low statistical power. 
Countries may use different methods to estimate the same indicator (e.g. HCV and HBV 
seroprevalence are estimated from diagnostic test results (programme data) and from seroprevalence 
studies (observational studies)), which can make inter-country comparability difficult. In order to 
mitigate the challenges arising from this diversity, we documented the common case definitions in the 
methods section and detailed some of the country-specific methodological characteristics in the 
annex tables. Whenever possible, we also illustrated each building block of the barometer with some 
case studies providing contextual information at country level.  
Some indicators have intrinsic limitations. For instance, while information on the prevalence of HCV 
antibodies is useful for assessing the proportion of PWID who have been exposed to the infection at 
some point in their life, it does not reflect the prevalence of chronic infections, since those who clear 
the infection (through natural clearance or through treatment) will still test positive for antibodies. As 
the number of patients successfully treated will increase, antibody prevalence will have more limited 
utility. Furthermore, the availability of an intervention (e.g. HBV vaccination routinely offered in prisons 
or reimbursement for treatment with no restrictions related to drug use) will not necessarily translate 
into a high coverage of the intervention among the target population. Other factors (stigma, medical 
habits) may play an important role. 
Conclusions 
Taking into account the above-mentioned limitations, the following conclusions can be drawn from the 
barometer. Regarding the availability of data documenting the context and needs, recent PWID 
estimates are available for only half of the countries, and only five countries report recent data on the 
prevalence of chronic and/or current HCV infections among PWID. The available data nevertheless 
show that PWID are disproportionally affected by HCV and HBV infections, as a result of sharing 
injecting equipment, making this group a key population for the elimination strategy. Injection of 
stimulants, driven by the increasing availability of stimulant drugs on the European drug market, 
increases the risk of blood-borne disease transmission among PWID, as documented in recent HIV 
outbreaks. 
As far as national policies are concerned, the 2030 Sustainable Development Goals have had an 
impact on the adoption of national hepatitis policies in Europe. This can be seen in the acceleration of 
policy development witnessed in recent years. It can also be seen in the content of policies adopted 
since 2015, which reflect countries’ commitments to the Sustainable Development Goal on health, 
often embracing the viral hepatitis elimination goal. All new policies consider people who inject drugs 
an important risk group. Nevertheless, in the last quarter of 2018, 11 EU Member States had yet to 
adopt an explicit viral hepatitis policy that was inclusive of PWID. 
TECHNICAL REPORT I Monitoring the elimination of viral hepatitis as a public health threat among people who inject drugs in 
Europe 
 
33 
 
The cost-effectiveness of prevention and harm reduction measures to reduce the transmission of 
infectious diseases among PWID, including viral hepatitis, is well documented. Prevention and harm 
reduction programmes are also key entry points for testing drug users for hepatitis, linking them to 
care and reducing the risk of reinfection after successful treatment. However, looking at the 
prevention building block of the barometer, the coverage of measures known to prevent HCV and 
HBV infections is suboptimal in many Member States. For example, only four countries have reached 
the 2020 WHO core target for clean needles/syringes distributed per person who injects drugs, while 
12 countries were below target and 14 countries did not provide the numerator and/or the 
denominator to compute this indicator. 
Testing for viral hepatitis is the first component of the cascade of care. Despite the fact that testing is 
offered in harm reduction services and in the prison system of a majority of countries, the low 
coverage of testing in the last year among PWID in the community reflects missed opportunities to 
diagnose people in these settings. There is currently no systematic collection of data on the HCV and 
HBV cascade of care for PWID in most countries. However, one case study showed that even in a 
country where there is no clinical or financial restriction on DAA access for PWID who are chronically 
infected with HCV, logistical and cultural barriers may prevent access to safe and effective treatment. 
When available, the proxy indicator included in the barometer to assess the impact of prevention and 
treatment on the incidence of HCV does not show any significant reduction in incidence during the 
period 2015-17. This should be interpreted cautiously. First, the indicator (anti-HCV prevalence 
among young and new injectors) may imperfectly reflect new transmission among PWID (because it is 
based on antibody biomarkers, has a small sample size and is prone to selection bias). Second, it 
may be too early to see the impact of a strategy that was put in place after 2016 in some countries. 
The data may nevertheless indicate that the current level of prevention, harm reduction and treatment 
among PWID is too low to achieve a significant reduction in the incidence of chronic HCV infections 
by 2020, as is also suggested by modelling work.  
Recommendations 
If monitoring data are to support the elimination of HCV and HBV as a public health threat, it will be 
essential to meet the basic data needs and document the extent of the problem, starting with the size 
of the target population (i.e. PWID) and the prevalence of chronic infections among PWID. For the 
former, crude indirect methods using information from surveys among PWID to get a treatment 
multiplier (Larney et al., 2017) or using capture-recapture studies (Raag et al., 2019), would constitute 
a first step for countries (or regions within countries) with no recent estimates. For the latter, 
introducing and reporting RNA test results in addition to antibody tests for HCV, as implemented in 
the routine monitoring system in the United Kingdom (Public Health England, 2018), would provide 
valuable information. If routine monitoring is not an option, well-designed (but resource-intensive) ad 
hoc seroprevalence studies, such as the DRUCK study conducted in eight German cities (Wenz et al., 
2016)., can provide a range of action-orientated information on HCV and HBV infection among PWID 
and related risk factors  
Having a national, well-funded hepatitis policy that is inclusive of PWID is not a sufficient condition for 
achieving the elimination targets, but is a necessary one. In order to help Member States to draft 
inclusive national hepatitis policies, policy documents relating to national plans already adopted in 
Europe are accessible from the EMCDDA’s online document library (EMCDDA, 2018) 
In order to support the implementation of evidence-based infectious disease prevention measures 
(including measures to prevent viral hepatitis), a number of public health guidance documents are 
available on the EMCDDA website. They include guidance on the prevention and control of infectious 
diseases among PWID (ECDC and EMCDDA, 2011), a European guide to health and social 
responses to drug problems (EMCDDA, 2017) and public health guidance on prevention and control 
of blood-borne viruses in prison settings (ECDC and EMCDDA, 2018b). 
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WHO guidance and ECDC and EMCDDA systematic reviews on HCV and HBV testing are available 
online (WHO, 2017b; ECDC, 2018d; ECDC and EMCDDA, 2018c). To support stakeholders in 
identifying barriers to testing in drug facilities and to provide solutions, the EMCDDA launched its 
‘testing initiative’ in 2018. It is based on three modules. Module 1 helps those tasked with planning 
and developing programmes to tackle HCV and associated health problems in an area to identify 
strengths and weaknesses in their current activities and barriers to and facilitators of improvements. It 
is based on a multidisciplinary workshop and supported by a range of materials: (i) information on 
epidemiological indicators and responses currently available; (ii) a checklist of questions to support 
the identification of barriers to and facilitators of testing; and (iii) links to materials to support action, 
such as guidelines and best practice. Module 2 supports response selection by pulling together 
information on best practice with a focus on important lessons concerning the implementation of 
programmes, modelled on the Xchange registry for prevention programmes. Module 3 provides 
practical implementation support: first, a knowledge-questionnaire aimed at staff in services, and 
second, material for people who inject drugs. 
The EMCDDA will update the elimination barometer annually with new data from the DRID network. 
The next DRID network meeting will provide the opportunity to work on improving the existing 
indicators, to explore the availability of additional ones (e.g. on cascade of care and the impact).
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Annexes 
ANNEX 1 
Current PWID population size, context and need, viral hepatitis elimination barometer for PWID 
(green = recent data available, grey = no data or no recent data) 
Category Context and need — epidemic pattern 
Subcategory Current PWID population size 
Indicator 
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Austria No data No data No data No data No data 2017 756 
Belgium 2015 (1) National (1) n.a. 23 828 (1) 3.28 (1) 2017 752 
Bulgaria 2004 Subnational Sofia 9 686 10 2017 576 
Croatia 2016 National  n.a.  6 344 2.21 No data No data 
Cyprus 2018 National n.a. 221 0.37 2017 113 
Czechia 2018 National n.a.  43 700 6.32 2017 1 723 
Denmark 2006 National n.a.  12 754 3.56 2017 258 
Estonia 2018 National n.a. 8 606 10 2016 181 
Finland 2014 National n.a. 15 611 4.6 2017 1 200 
France 2018 National n.a. 117 000 2.89 2017 4 676 
Germany No data No data No data No data No data 2016 6 157 
Greece 2018 National n.a. 3 655 0.53 2017 832 
Hungary 2016 National n.a. 6 707 0.98 2017 118 
Ireland No data No data No data No data No data 2017 1 093 
Italy No data No data No data No data No data 2017 8 533 
Latvia 2018 National n.a. 7 715 6.1 2017 344 
Lithuania 2017 National n.a. 8 868 4.63 No data No data 
Luxembourg 2017 National n.a. 1 467 3.77 2017 128 
Malta No data No data No data No data No data No data No data 
Norway 2018 National n.a.  8 682 2.52 No data No data 
Poland 2005 Subnational Warsaw 1 480-1 940 1.2-1.6 2017 840 
Portugal 2017 National n.a. 13 162 2.06 2017 235 
Romania 2017 Subnational Bucharest 9 030 5.13 2017 712 
Slovakia 2006 National n.a. 18 841 4.86 2017 825 
Slovenia 2001 National n.a. 7 320 5.2 2017 83 
Spain 2018 National n.a. 12 684 0.41 2016 2 621 
Sweden 2015 National n.a.  8 021 1.8 2017 331 
Netherlands 2017 National n.a. 840 0.08 2015 70 
Turkey No data No data No data No data No data 2017 1 858 
United Kingdom 2011 National n.a. 122 894 3 2017 18 319 
(1) Ever injectors. 
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ANNEX 2 
Risk factors, context and need, viral hepatitis elimination barometer for PWID (green = recent 
data available, grey = no data or no recent data) 
Category Context and need — epidemic pattern 
Subcategory 
Risk factors 
Drug Sharing (studies) Sharing (drug treatment entrants) 
Indicator 
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Austria Heroin No data No data No data No data No data 2017 235 6.8 
Belgium Heroin 2017 Sub-nat Flanders 241 26.5 2017 337 12.8 
Bulgaria Heroin 2016 Sub-nat 5 cities 421 47 2017 242 14 
Croatia Heroin 2007 Sub-nat 4 cities 364 6.4-17 No data No data No data 
Cyprus Heroin 2015 National n.a. 88 20 2017 69 14.5 
Czechia Methamphetam. 2016 National n.a. 962 10 2017 919 12.7 
Denmark Heroin No data No data No data No data No data 2014 463 24.2 
Estonia Fentanyl 2017 Sub-nat Tallin 112 10.7 No data No data No data 
Finland Buprenorphine 2009 Sub-nat 9 cities 639 29 2017 348 23.9 
France Heroin 2015 National n.a.  1367 14.5 2017 1359 5.9 
Germany Heroin 2014 Sub-nat Hambourg 273 10.6 No data No data  No data 
Greece Heroin 2013 National Attica 850 15-67 No data No data No data 
Hungary Heroin 2015 National n.a. 378 39 No data No data No data 
Ireland Heroin No data No data No data No data No data 2017 506 15.4 
Italy Heroin 2000 National n.a. 916 9 No data No data No data 
Latvia Heroin 2017 Sub-nat 10 cities 536 2.1 2017 165 4.2 
Lithuania Heroin 2014 Sub-nat 3 cities 200 14 No data No data No data 
Luxembourg Heroin 2017 National n.a. 42 31 2017 103 7.8 
Malta Heroin No data No data No data No data No data 2017 711 2.1 
Norway Amphetamine 2012 Sub-nat Oslo 91 13 No data No data No data 
Poland Heroin 2017 National n.a. 119 17.7 2017 558 10.2 
Portugal Heroin No data No data No data No data No data 2017 165 7.9 
Romania Heroin 2015 Sub-nat Bucharest 516 40 2017 457 9.6 
Slovakia Heroin No data No data No data No data No data 2017 623 17 
Slovenia Heroin No data No data No data No data No data 2017 63 4.8 
Spain Heroin No data No data No data No data No data 2016 695 5.3 
Sweden No data 2013 Sub-nat 7 cities 173 62 No data No data No data 
The 
Netherlands Heroin 2010 Sub-nat Rotterdam 49 27 No data No data No data 
Turkey Heroin 2010 National n.a. 877 43 2017 1 858 54 
United 
Kingdom Heroin 2017 
Subnation
al E, W & NI 1 281 18 2017 1 424 19.8 
Sub-nat= sub-national, E, W & NI= England, Wales and Northern Ireland
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ANNEX 3 
Prevalence of HCV and HBV, context and need, viral hepatitis elimination barometer for PWID 
(green = recent data available, grey = no data or no recent data) 
SP: seroprevalence study, DT: diagnostic test; DTC: drug treatment centre; LTS: low-threshold services; NSP: needle and 
syringe programme; PRI: prison; STI: Sexually Transmitted Infections Clinics, PHL: Public Health Laboratories; HTC: HIV 
Testing Centres; STR: Street; OTH: Other, RDS: Respondent-driven sampling; LM: last month; LY: last year
Category Context and need — epidemic pattern 
Subcategory Prevalence of HBV and HCV 
Indicator 
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Austria DT DTC/LTS/NSP Ever n.a. 2017 433 60.0-83.5 35.3-55.6 2017 272 2.6 
Belgium DT DTC/NSP Ever n.a. 2015-16 71 22.0-33.3 No data 2015 18 5.6 
Bulgaria DT DTC Current LM 2017 319 76.8 No data 2017 98 5.1 
Croatia SP NSP Current LM 2014 817 38.3 No data 2008 192 0 
Cyprus DT DTC/PRI Ever n.a. 2017 76 56.6 No data 2017 72 5.6 
Czechia DT NSP Current LY 2017 2 044 14.7 No data n.a. n.a. No data 
Denmark No data No data No data  No data  No data No data n.a. n.a. No data 
Estonia SP LTS Current LM 2017 112 89.3 No data 2013 326 4 
Finland SP NSP Current LM 2014 589 74 No data n.a. n.a. No data 
France SP NSP/LTS/DTC Ever n.a. 2011 901 63.8 No data 2011 908 0.81 
Germany SP LTS/RDS Current LY 2011-14 2 077 36.9-73.0 23.1-54.0 2011-14 
2 07
7 0.3-2.3 
Greece DT DTC/LTS/PRI Ever n.a. 2017 847 66.5 No data 2017 871 2.1 
Hungary SP DTC/NSP/LTS Ever n.a. 2015 559 49.7 No data 2015 596 2.2 
Ireland SP PRI Ever n.a. 2010 200 41.5 No data 2010 200 0.5 
Italy DT DTC Ever n.a. 2017 7 805 64.3 No data n.a. n.a. No data 
Latvia SP  STR Current  2017 386 85.2 No data 2017 386 3.6 
Lithuania SP NSP Current LM 2014 200 77 No data 2014 200 10.5 
Luxembourg DT DTC/NSP/STI/PRI Ever n.a. 2017 66 75.8 53.0 2005 255 3.9 
Malta DT DTC/PHL/STI Current LM 2017 119 44.5 No data n.a. n.a. No data 
Norway SP DTC Current  2017 6 104 49.7 No data 2015 227 0.9 
Poland SP NSP/LTS/HTC Ever n.a. 2017 171 57.9 No data 2017 172 2.9 
Portugal DT DTC Ever n.a. 2017 367 81.5 No data 2017 355 3.1 
Romania SP STR Ever n.a. 2015 522 75.7 No data 2015 522 10.5 
Slovakia SP DTC Ever n.a. 2017 52 42.3 No data 2017 54 3.7 
Slovenia DT DTC Ever n.a. 2017 61 42.6 No data 2002 564 3.4 
Spain DT DTC/PRI Ever n.a. 2016 4 265 64.4 No data 2016 1 993 9.4 
Sweden DT PRI Ever n.a. 2013 62 96.8 No data n.a. n.a. No data 
Netherlands DT DTC Ever n.a. 2017 14 85.7 No data 2017 16 6.3 
Turkey SP DTC Ever n.a. 2017 2 366 45.8 No data 2017 2 366 2.2 
United 
Kingdom SP DTC/NSP/LTS Ever n.a. 2017 3 119 22.5-52.2 25.7 2017 
3 09
6 0.2-0.9 
TECHNICAL REPORT I Monitoring the elimination of viral hepatitis as a public health threat among people who inject drugs in 
Europe 
 
42 
 
ANNEX 4 
Inputs and prevention, viral hepatitis elimination barometer for PWID (green = target reached or 
intervention implemented, red = target not reached or intervention not fully implemented, grey = no 
data) 
Category Inputs Prevention 
Subcategory Policy NSP coverage OST coverage HBV vaccine 
Indicator 
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Austria in preparation 2017 6 293 593 No data 2017 18 632 50 Available 
Belgium Yes 2017 1 203 077 50 2017 16 546 No data Available 
Bulgaria No 2017 52 927 No data 2017 3 247 No data Not available 
Croatia No 2017 244 299 192 2017 4 792 54 Available 
Cyprus No 2017 245 1 2017 209 18 No data 
Czechia in preparation 2017 6 409 862 147 2017 5 000 38 Not available 
Denmark Yes No data No data No data 2015 7 050 No data Available 
Estonia No 2017 1 997 158 232 2017 1 186 No data Available 
Finland Yes 2017 5 824 467 373 2015 3 329 No data Available 
France Yes 2015 11 907 416 102 2017 178 665 85 Available 
Germany Yes No data No data No data 2017 78 800 54 Available 
Greece Yes 2017 278 415 76 2017 9 388 65 Available 
Hungary No 2017 137 580 21 2015 669 No data Available 
Ireland Yes 2017 519 578 No data 2017 10 316 54 Available 
Italy Yes 2017 515 445 No data 2017 69 642 30 Available 
Latvia Yes 2017 833 817 108 2017 669 9 Not available 
Lithuania No 2017 251 370 28 2017 1 136 15 Not available 
Luxembourg Yes 2017 447 681 305 2017 1 142 66 Available 
Malta Yes 2017 315 541 No data 2017 1 025 72 Available 
Norway Yes 2017 2 884 230 332 2017 7 622 No data Available 
Poland in preparation 2017 59 958 No data 2017 2 685 18 Available 
Portugal Yes 2017 1 421 666 108 2017 16 888 45 Available 
Romania in preparation 2017 1 095 287 No data 2017 1 530 8 Not available 
Slovakia No 2017 395 877 No data 2017 620 No data Available 
Slovenia Yes 2017 578 926 No data 2016 3 042 62 Available 
Spain Yes 2016 1 503 111 119 2016 58 749 No data Available 
Sweden Yes 2017 517 381 No data 2017 4 468 No data Available 
Netherlands Yes No data No data No data 2014 5 241 No data Available 
Turkey No data n.a. n.a. n.a. 2011 12 500 No data No data 
United Kingdom Yes 2017 7 341 774 No data 2017 149 420 57 Available 
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ANNEX 5 
Testing, viral hepatitis elimination barometer for PWID (green = target reached or intervention 
implemented, red = target not reached or intervention not fully implemented, grey = no data) 
Category Testing 
Subcategory Testing availability 
HCV testing coverage 
Studies TDI 
Indicator 
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Austria Yes Available  n.a. n.a. n.a. n.a. No data 2017 258 72.5 
Belgium Yes Available n.a. n.a. n.a. n.a. No data n.a. n.a. No data 
Bulgaria Yes Not routine 2016 Current 421 Yes 45 2017 253 75.5 
Croatia No Available n.a. n.a. n.a. n.a. No data n.a. n.a. No data 
Cyprus No Available 2015 Ever 52 Yes 33 2017 71 49.3 
Czechia Yes Not routine 2016 Current 962 No 66.9 2017 690 57.7 
Denmark Yes No data n.a. n.a. n.a. n.a. No data 2017 81 35.8 
Estonia Yes Available 2017 Current 24 No 45.8 n.a. n.a. No data 
Finland Yes Available 2009 Current 689 No 47.2 2017 358 46.6 
France Yes Available 2015 Ever 1 127 Yes 65.8 n.a. n.a. No data 
Germany Yes Available 2014 Current 101 Yes 46.5 n.a. n.a. No data 
Greece Yes Not routine 2013 Ever 829 No 47-65 n.a. n.a. No data 
Hungary Yes Not routine 2015 Ever 420 Yes 37.6 n.a. n.a. No data 
Ireland Yes Available n.a. n.a. n.a. n.a. No data 2017 360 46.4 
Italy Yes Available n.a. n.a. n.a. n.a. No data n.a. n.a. No data 
Latvia Yes Not routine 2017 Current 394 No 93.4 2017 148 17.6 
Lithuania No Available 2006 Unknown 320 No 100 n.a. n.a. No data 
Luxembourg Yes Available 2007 Ever 164 No 84 2017 68 92.6 
Malta Yes No data n.a. n.a. n.a. n.a. No data 2017 696 12.4 
Norway No data Available 2012 Current 89 No 36 n.a. n.a. No data  
Poland No Not routine 2017 Ever 38 Yes 15.8 2017 594 38.9 
Portugal Yes Available n.a. n.a. n.a. n.a. No data 2017 193 19.7 
Romania Yes Not routine 2015 Ever 516 Yes 7.4 2017 547 44.8 
Slovakia No Not routine 2017 Ever 51 Yes 58.8 n.a. n.a. No data 
Slovenia No data Available n.a. n.a. n.a. n.a. No data 2017 62 32.3 
Spain Yes Available n.a. n.a. n.a. n.a. No data 2016 804 50.4 
Sweden Yes Available 2013 Ever 173 No 13 n.a. n.a. No data 
Netherlands Yes Available 2010 Ever 50 No 6 n.a. n.a. No data 
Turkey No data No data 2008 Current 168 No 1 2017 1 858 38.2 
United 
Kingdom Yes Available 2017 Ever 597 No 95.8 n.a. n.a. No data 
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ANNEX 6 
Testing and treatment, viral hepatitis elimination barometer for PWID (green = target reached or 
intervention implemented, red = target not reached or intervention not fully implemented, grey = no 
data) 
Category Testing HCV treatment 
Subcategory 
New notifications of HCV and HBV cases linked to injecting drug use 
DAA accessibility 
for PWID 
Acute HCV Chronic HCV 
Unknow
n stage 
HCV 
Acute HBV Chronic HBV 
Unknow
n stage 
HBV 
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Austria 19 5 6 22 5 9 0 2 1 0 No No 
Belgium No data No data No data No data 0 No data No data No data No data 0 No No 
Bulgaria No data No data No data No data No data No data No data No data No data No data Restrictions Restrictions 
Croatia No data No data No data No data No data No data No data No data No data No data Restrictions Restrictions 
Cyprus No data No data 10 2 0 50 0 6 0 0 Restrictions Restrictions 
Czechia 0 0 0 0 No data 0 0 0 0 0 No No 
Denmark 100 2 87 81 0 100 0 55 6 0 No No 
Estonia 67 1 41 34 No data 33 0 20 0 No data Restrictions No 
Finland No data No data No data No data 536 0 0 14 2 No data No No 
France No data No data No data No data No data 46 2 No data No data No data No No 
Germany No data No data No data No data 877 9 16 No data No data 21 No No 
Greece 0 0 0 0 No data 0 0 No data No data No data No No 
Hungary 27 3 No data No data No data 12 2 No data No data No data No No 
Ireland 100 12 96 62 134 60 1 15 3 0 No No 
Italy 77 22 No data No data No data 68 15 No data No data No data No No 
Latvia 71 9 29 350 No data 70 12 12 21 No data No No 
Lithuania 28 6 No data No data No data 43 1 No data No data No data No No 
Luxembourg No data No data No data 0 29 No data No data 0 0 0 No No 
Malta 100 0 100 2 1 50 0 24 0 0 No No 
Norway No data No data No data No data 341 95 4 8 6 No data No No 
Poland 100 0 93 87 136 73 1 86 2 19 Restrictions Restrictions 
Portugal 58 0 69 0 0 37 0 39 0 0 No No 
Romania 52 2 0 0 No data 45 2 0 0 No data Restrictions Restrictions 
Slovakia 94 7 76 73 No data 61 7 47 1 No data Restrictions Restrictions 
Slovenia 17 1 2 0 No data 13 0 3 0 0 No No 
Spain 20 2 2 3 12 10 1 No data No data No data No No 
Sweden 81 104 68 589 46 58 4 24 13 0 No No 
Netherlands 78 2 No data No data No data 72 0 58 5 0 No No 
Turkey No data No data No data No data No data No data No data No data No data No data No data No data 
United 
Kingdom 0 0 0 0 0 0 0 0 0 0 No No 
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ANNEX 7 
Impact, viral hepatitis elimination barometer for PWID (grey = no data) 
Category Impact 
Subcategory 
Incidence proxy: anti-HCV prevalence among young and new injectors 
Baseline prevalence (2015 or prior) Prevalence after 2015 
Indicator 
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Austria 2015 31 53.3-62.5 24 41.7 2017 12 83 No data No data 
Belgium 2014 10 10 15 60 No data No data No data No data No data 
Bulgaria 2015 86 52 29 55 2017 12 42 No data No data 
Croatia 2007 109 9.7-48.0 34 59 No data No data No data No data No data 
Cyprus 2011 12 50 n < 10 n < 10 2017 n < 10 n < 10 n < 10 n < 10 
Czechia 2015 171 14 59 8.5 2017 294 12 148 11 
Denmark No data No data No data No data No data No data No data No data No data No data 
Estonia 2014 24 33 13 23 No data No data No data No data No data 
Finland 2014 82 46 15 6.7 No data No data No data No data No data 
France 2011 58 10 32 7.5 No data No data No data No data No data 
Germany 2011-14 120 5.7-50.0 39 0.0-36.0 No data No data No data No data No data 
Greece 2015 134 50-79 71 29.4-50 2017 43 67 51 43 
Hungary 2015 71 37 29 31 No data No data No data No data No data 
Ireland 2010 44 9.1 28 3.6 No data No data No data No data No data 
Italy 2015 334 28.7 No data No data 2017 267 33.7 No data No data 
Latvia 2014-15 45 40 23 34.8 2017 11 45.5 30 23.3 
Lithuania 2014 24 67 No data No data No data No data No data No data No data 
Luxembourg 2005 111 22-78 No data No data No data No data No data No data No data 
Malta 2015 13 23 No data No data 2017 n < 10 n < 10  No data 
Norway No data No data No data No data No data No data No data No data No data No data 
Poland No data No data No data No data No data 2017 31 19.3 32 25 
Portugal 2012 10 60 n < 10 n < 10 2017 n < 10 n < 10 n < 10 n < 10 
Romania 2015 83 67 20 45 No data No data No data No data No data 
Slovakia 2015 11 54.6 n < 10 n < 10 2017 12 42 24 21 
Slovenia 2011-12 11 9.1 13 15.4 2017 n < 10 n < 10 n < 10 n < 10 
Spain 2015 39 20.5 48 29.2 2016 62 18 61 28 
Sweden 2009-10 18 28 16 25 No data No data No data No data No data 
Netherlands 2015 n < 10 n < 10 n < 10 n < 10 2017 n < 10 n < 10 n < 10 n < 10 
Turkey 2015 1173 30.1 222 24.3 2017 824 37 78 29 
United 
Kingdom 2015 241 13-50 335 
25.2-
31.2 2017 91 22-27 243 
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